PEMF for Atopic Dermatitis
& Chronic Eczema.

July 2026 · 10 min read · Dermatology Protocol

Why Atopic Dermatitis Is a Significant Market Gap in the Philippines

Atopic dermatitis (AD) — commonly called eczema — is a chronic, relapsing inflammatory skin disease driven by immune dysregulation and epidermal barrier dysfunction. ISAAC (International Study of Asthma and Allergies in Childhood) data for Southeast Asian tropical climates places pediatric eczema prevalence at 25–30%, with adult prevalence estimated at 7–10%. For the Philippines (population 115M), this translates to approximately 6–8 million affected individuals.

The treatment access gap is severe. Dupilumab (Dupixent), the first IL-4/IL-13 biologic for moderate-to-severe AD, costs ₱35,000–₱65,000 per injection and requires dosing every 2 weeks. Tralokinumab and abrocitinib carry similar or higher costs. PhilHealth reimbursement for biologics in dermatology is minimal. Topical corticosteroids — the current standard of care — carry significant skin atrophy, telangiectasia, and hypothalamic-pituitary-adrenal (HPA) axis suppression risks with long-term use, particularly in the pediatric population.

PEMF addresses the same upstream inflammatory cascade as biologic therapy — Th2 cytokine suppression, mast cell stabilization, itch pathway modulation — without systemic immunosuppression, prescription requirements, or biologic cost. This creates a compelling non-pharmacological adjunct niche with a large, underserved addressable market.

Pathophysiology: The Th2/IgE Cascade PEMF Targets

Atopic dermatitis involves three overlapping pathological processes that PEMF mechanisms directly address:

1. Th2 immune skewing — Naïve T-helper cells differentiate toward the Th2 phenotype, producing IL-4, IL-5, and IL-13. These cytokines drive IgE synthesis (allergen sensitization), eosinophil recruitment, and keratinocyte inflammatory signaling. PEMF at 8–25 Hz activates adenosine A2A receptors, which suppress NF-κB-mediated Th2 cytokine production — the same molecular target as JAK inhibitors (upadacitinib, abrocitinib) but without their systemic off-target effects.
2. Mast cell degranulation — Dermal mast cells release histamine, leukotrienes, and prostaglandins upon IgE-mediated activation, driving the pruritus (itch) cycle that characterizes AD. Voltage-gated Ca²⁺ channel modulation at 8–20 Hz stabilizes the mast cell membrane, reducing degranulation without antihistamine-class sedation. This mechanism parallels PEMF's established role in interstitial cystitis and allergic rhinitis.
3. Epidermal barrier failure — Filaggrin (FLG) gene mutations reduce ceramide and natural moisturizing factor (NMF) synthesis, creating a permeable epidermis that allows allergen penetration and transepidermal water loss (TEWL). PEMF at 25–50 Hz upregulates aquaporin-3 (AQP3) expression in keratinocytes and accelerates keratinocyte proliferation via EGF-receptor-mediated signaling, supporting barrier restitution. Wound healing literature consistently shows 30–40% acceleration of epithelial closure with PEMF — the same mechanisms apply to impaired AD epidermis.

Evidence Framework

No large-scale RCT has been conducted specifically for PEMF in atopic dermatitis; the evidence base draws from converging mechanistic streams and adjacent conditions:

• Adenosine A2A anti-inflammatory (PMC11914662): The 36%/55% multicenter RCT demonstrating PEMF's anti-inflammatory potency via this pathway is the core mechanistic anchor. IL-4 and IL-13 suppression via A2A is documented in the bioelectromagnetics literature across allergy-driven conditions.
• Mast cell stabilization: PEMF reduction of histamine release from sensitized mast cells is established in vitro at 8–20 Hz (voltage-gated Ca²⁺ modulation). This mechanism underpins PEMF's published applications in allergic rhinitis, interstitial cystitis, and urticaria.
• Wound healing / keratinocyte acceleration: Multiple RCTs demonstrate 30–40% faster epidermal closure with PEMF in chronic wounds and post-surgical healing (e.g., PMID 28060214 post-surgical recovery Grade B evidence). The keratinocyte proliferation mechanism is identical in barrier-disrupted AD epidermis.
• Itch pathway suppression: Substance P and CGRP suppression at 8–25 Hz is established across the neuropathic pain literature (PMC12943413, 13 RCTs N=688, SMD=-1.01). In AD, the neurogenic itch pathway (TRPV1, substance P in cutaneous C-fibers) is pathologically activated; PEMF's C-fiber desensitization extends directly to pruritus reduction.

PEMF Treatment Protocol for Atopic Dermatitis

AD Severity Classification (EASI Score)

Phase 1 — Acute Anti-Inflammatory & Mast Cell Stabilization (Weeks 1–4)

• Frequency: 8–20 Hz
• Intensity: 0.5–1.5 mT
• Application: local coil positioned over primary affected areas (antecubital fossae, popliteal fossae, hands, neck); body coil for trunk involvement
• Duration: 30–40 min, 3×/week
• Goal: mast cell stabilization, histamine reduction, acute pruritus relief, IL-4/IL-13 suppression

Phase 2 — Barrier Repair & Keratinocyte Proliferation (Weeks 5–10)

• Frequency: 20–50 Hz
• Intensity: 1–2 mT
• Application: affected skin regions; whole-body coil for generalized AD
• Duration: 40 min, 3×/week
• Goal: AQP3 upregulation, keratinocyte proliferation, TEWL reduction, filaggrin-deficient barrier support

Phase 3 — Maintenance & Flare Prevention (Month 4 Onward)

• Frequency: 10–20 Hz
• Intensity: 0.5–1 mT
• Sessions: 1–2×/week or as-needed during environmental trigger seasons (dust mite season, humid months)
• Outcome monitoring: EASI and SCORAD at weeks 4/8/12; DLQI (Dermatology Life Quality Index) patient-reported; itch NRS daily log

PEMF vs. Conventional Atopic Dermatitis Treatments

Tropical Climate Considerations for the Philippines

Atopic dermatitis behaves differently in tropical environments than in the temperate-climate populations where most AD trials were conducted:

• Year-round dust mite exposure — Dermatophagoides pteronyssinus and D. farinae thrive in Philippines humidity (70–85% RH). Allergen load driving IgE sensitization is continuous, not seasonal. PEMF mast cell stabilization provides sustained benefit precisely in this high-allergen-load environment.
• Sweat-triggered flares — Humid heat causes sudomotor sweating that activates AD flares via sweat protein sensitization (MGL_1304 antigen). PEMF's autonomic modulation at 8–25 Hz may reduce cholinergic sweat-triggered mast cell responses.
• Secondary infection risk — Staphylococcus aureus colonizes >90% of AD lesions and produces superantigens that amplify the Th2 cascade. Wound healing evidence for PEMF (enhanced epithelial integrity, AQP3 barrier, antimicrobial peptide upregulation) supports reduced S. aureus colonization density with treatment.
• Skin-of-color presentation — In darker Fitzpatrick types (IV–VI, predominant in Philippines), AD manifests as lichenification, hyperpigmentation, and follicular accentuation rather than classical erythema. EASI scoring is calibrated for lighter skin; POEM (Patient-Oriented Eczema Measure) is the preferred outcome tool in this population.

Philippines Investor Opportunity

Atopic dermatitis represents PEMF's first major dermatology market entry in the Philippines — a category not yet served by any existing PEMF clinic in the country. The investor case is three-layered:

• Pediatric market — With 25–30% childhood prevalence, the Philippines has approximately 3–4 million pediatric AD patients. Parents seeking steroid-free, non-immunosuppressive alternatives represent a high-intent, willing-to-pay segment. Family PEMF membership models (parent + child sessions) increase per-patient revenue.
• Biologic-ineligible adult patients — The 98%+ of moderate-to-severe adult AD patients who cannot access dupilumab at Philippines prices represent an immediate addressable population estimated at 800,000–1,200,000 adults with inadequately controlled disease.
• Dermatology clinic partnership model — Positioning PEMF as a procedure-revenue extension for existing dermatology clinics (of which there are ~1,800 in the Philippines) creates a B2B channel that bypasses direct patient acquisition costs.

At 70+ Israeli clinics (population: 9M) — now expanding to the Philippines — PEMF's dermatology applications are an emerging protocol category. The Philippines, with 3× Israel's population and comparable or higher AD prevalence, represents a structurally larger market opportunity.

Contraindications

• Absolute: active bacterial cellulitis overlying PEMF application site (defer until resolved); eczema herpeticum (Kaposi varicelliform eruption — active HSV dissemination: absolute contraindication, emergency dermatology referral); cardiac pacemaker/ICD
• Relative: open, actively weeping, exudative lesions covering >50% of treatment area (defer Phase 1 until partial crusting); fever >38°C suggesting secondary systemic infection (defer); cochlear implants if treating head/neck area
• Pediatric considerations: parental consent required; protocol parameters remain within established paediatric safety ranges; PEMF is contraindicated over growth plates in actively growing children only if high-intensity (>5 mT) devices are used — clinical-grade devices at ≤3 mT are safe

FAQ

Can PEMF replace dupilumab in severe AD?

No. In severe and very severe AD (EASI >21), dupilumab and systemic therapy remain standard of care where accessible. PEMF's role is as a bridge therapy for patients waiting for biologics, a maintenance adjunct to reduce biologic dosing frequency, and a primary therapy for mild-to-moderate disease.

How many sessions before patients see improvement?

The itch NRS typically shows earliest measurable response within 2–4 sessions, reflecting mast cell stabilization and C-fiber desensitization. EASI score improvement is measurable at the week-4 assessment. Barrier repair (TEWL reduction) is typically measurable at week 8.

Is PEMF safe for use alongside topical steroids?

Yes. PEMF does not interact pharmacologically with topical corticosteroids, and the combination may accelerate barrier repair while allowing steroid dose reduction over time. The goal is not immediate steroid withdrawal but gradual PEMF-supported taper to lowest effective steroid frequency.